How to Build Your Biotech Company in 2024 (According to Founders)

11 October 2024

Angiex Featured in Labiotech’s Guide to Building a Biotech Company

Angiex was highlighted as one of only a handful of companies in Labiotech’s expert feature on building a successful biotech startup. In the article, Angiex’s CEO, Paul Jaminet, shared insights on how the supportive ecosystem in Cambridge has been essential to Angiex’s growth.

“For entrepreneurs, the advantage of having ready access to expertise, capital, and a company incubation ecosystem is hard to overstate,” Jaminet noted. He emphasized that the resources and community in Cambridge made it “immensely helpful” for Angiex to operate efficiently and advance its pioneering TM4SF1-directed therapies.

Labiotech’s recognition of Angiex highlights the company’s innovation in the biotech space and the importance of its location in fueling its progress toward next-generation cancer treatments. To see the entire story, read on.


About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...